Themed Section: Redox Biology and Oxidative Stress in Health and Disease

REVIEW ARTICLE

Targeting the NO/superoxide ratio in adipose tissue: relevance to obesity and diabetes management

Correspondence
Professor Bato Korac, Department of Physiology, Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Bulevar despot Stefan 142, 11060 Belgrade, Serbia. E-mail: koracb@ibiss.bg.ac.rs

Received 18 January 2016; Revised 31 March 2016; Accepted 4 April 2016

Aleksandra Jankovic1, Aleksandra Korac2, Biljana Buzadzic1, Ana Stancic1, Vesna Otasevic1, Péter Ferdinandy3,4, Andreas Daiber5 and Bato Korac1

1Department of Physiology, Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia, 2Faculty of Biology, Center for Electron Microscopy, University of Belgrade, Belgrade, Serbia, 3Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, 4Pharmahungary Group, Szeged, Hungary and 5Center for Cardiology - Cardiology 1, Molecular Cardiology, University Medical Center Mainz, Germany

Insulin sensitivity and metabolic homeostasis depend on the capacity of adipose tissue to take up and utilize excess glucose and fatty acids. The key aspects that determine the fuel-buffering capacity of adipose tissue depend on the physiological levels of the small redox molecule, nitric oxide (NO). In addition to impairment of NO synthesis, excessive formation of the superoxide anion (O2•−) in adipose tissue may be an important interfering factor diverting the signalling of NO and other reactive oxygen and nitrogen species in obesity, resulting in metabolic dysfunction of adipose tissue over time. Besides its role in relief from superoxide burst, enhanced NO signalling may be responsible for the therapeutic benefits of different superoxide dismutase mimetics, in obesity and experimental diabetes models. This review summarizes the role of NO in adipose tissue and highlights the effects of NO/O2•− ratio ‘teetering’ as a promising pharmacological target in the metabolic syndrome.

LINKED ARTICLES
This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc

Abbreviations
AMPK, AMP-activated protein kinase; BH4, tetrahydrobiopterin; CcOx, cytochrome c oxidase; ETC, electron transport chain; IR, insulin receptor; IRS-1, insulin receptor substrate 1; MnSOD, manganese superoxide dismutase; NOX, NADPH oxidase; OXPHOS, oxidative phosphorylation; PGC-1α, PPARγ coactivator 1α; PEPCK-C, cytosolic phosphoenolpyruvate carboxykinase; PTP, protein tyrosine phosphatase; RNS, reactive nitrogen species; sGC, soluble guanylate cyclase; SNO, S-nitrosothiol; TAG, triacylglycerol; Trx, thioredoxin; UCP, uncoupling protein; XO, xanthine oxidoreductase
Tables of Links

| TARGETS | LIGANDS |
|---------|---------|
| **Enzymes**<sup>a</sup> | **Adiponectin** |
| AMPK | BH4, tetrahydrobiopterin |
| eNOS | GSH |
| sGC, soluble guanylyl cyclase | NO |
| iNOS | |
| nNOS | |
| PDE3B | |
| PKB/Akt | |
| XO, xanthine oxidoreductase | |
| **Catalytic receptors**<sup>b</sup> | |}

These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (<sup>a,b,c,d,e</sup> Alexander et al., 2015a,b,c,d,e).

Introduction

The majority of type 2 diabetes cases (up to 90%) are related to insulin resistance and obesity (Anderson et al., 2003), suggesting a causal connection between these conditions (Berger, 1992; Daly, 1994). According to the dynamic nature of energy balance maintenance (and long-term mechanisms of adiposity regulation), increase in energy uptake is paralleled by energy expenditure by peripheral tissues, including adipose tissue, and obesity develops when fuel intake chronically exceeds expenditure (Hill and Peters, 1998; Kashyap and Defronzo, 2007). The failure of adipose tissue expansion (not obesity per se) is the essential factor linking positive energy balance, diabetes and other cardiometabolic diseases (Lafontan, 2013). Thus, when the inflows of nutrients into adipose tissues exceed the capability of adipocytes to handle nutrient excess and the capacity of adipose tissue to expand by hyperplasia, more adipocytes become hypertrophic and defend themselves by developing insulin insensitivity (Gray and Vidal-Puig, 2007). Improper lipolytic and lipogenic response of adipose tissue during fasting/feeding conditions in either case results in overflow and ectopic deposition of lipids in non-adipose organs (Frayn, 2002). According to the lipid overflow hypothesis of systemic insulin resistance development (Unger, 2003), fat-specific insulin resistance is the earliest risk factor for systemic insulin resistance and type 2 diabetes pathogenesis. Thus, clarification of the molecular mechanisms underlying the lipid buffering capacity of adipose tissue, that is, oxidative capacity and insulin sensitivity, may aid in the improvement of therapeutic options for obesity and diabetes prevention.

Nitric oxide (NO) has emerged as a central regulator of energy metabolism and body composition that acts mainly by modulating the oxidative capacity and insulin sensitivity of adipose tissue (see Jobgen et al., 2006; Dai et al., 2013; Bernlohr, 2014; Sansbury and Hill, 2014). Supraphysiological production of NO by inducible NO synthase (iNOS) in adipocytes (Merial et al., 2000) and macrophages (Weisberg et al., 2003; Lumeng et al., 2007) and lack of endothelial NOS (eNOS)-mediated NO synthesis (Valerio et al., 2006) in adipose tissue are important risk factors leading to obesity. Moreover, uncontrolled flux of superoxide anion (O2•−) from the electron transport chain (ETC) in mitochondria and NADPH oxidase (NOX) under persistent nutrient inflow into adipocytes may divert the role of NO in hypertrophic adipocytes, leading to local and ultimately systemic insulin resistance and type 2 diabetes (see Maritim et al., 2003; Bashan et al., 2009; Afanas’ev, 2010). The current review discusses the underlying mechanisms and consequences of impairment of physiological signalling of reactive oxygen and nitrogen species (ROS/RNS) in adipose tissue, their effects on lipid buffer function, and implications in the development of obesity and obesity-related type 2 diabetes.

Adipose organ and roles in metabolic homeostasis: healthy and unhealthy expansion

The function of adipose tissue in buffering daily lipid flux is traditionally understood as hydrolysis of triacylglycerol (TAG) and (re)esterification (Frayn, 2002). Compared with the other insulin-sensitive tissues, such as liver and muscle, adipose tissue is less important for postprandial glucose clearance, and the energy for cellular functions in adipocytes is primarily obtained via glycolytic ATP production. However, it appears that glucose uptake and metabolism as well as the oxidative capacity of adipocytes underlie metabolic flexibility and healthy expansion of adipose tissue during overnutrition and influence its role in protecting non-adipose tissues against lipotoxicity. The metabolic pathways facilitating adipocyte energy storage and release during fasting/feeding transitions have been recently reviewed in detail by Rutkowski et al. (2015) and briefly presented in Figure 1.

Fat cells (white adipocytes) compose the largest adipocyte population of human adipose tissue (Figure 2). Adipocytes may additionally be brown or brte/beige according to their origin (endothelial or myogenic) and ultrastructure. The
appearance and distinct origins of adipocytes reflect their specialization in energy partitioning. All adipocytes store excess calories as TAG, while brown and brite/beige cells are highly specialized for calorie combustion, specifically metabo-regulatory and/or thermo-regulatory thermogenesis. The metabolic inefficiency of these adipocytes is attributed to high mitochondrial content and the uncoupling protein 1 (UCP1), a protonophore that uncouples oxidative phosphorylation (OXPHOS) from respiration, generating heat instead of ATP (Cannon and Nedergaard, 2004). Generally, the number of brown and beige adipocytes found in white areas varies with age, strain and environmental conditions (Cinti, 2000). The number of brown adipocytes in humans is inversely correlated with body mass index and body fat mass (van Marken Lichtenbelt et al., 2009) as well as fasting glycaemia (Cypess et al., 2009) and positively correlated with resting metabolic rate (van Marken Lichtenbelt et al., 2009). The real significance of brown adipose tissue in overall human metabolism and energy expenditure is yet to be established (Kozak et al., 2010; Schlögl et al., 2013; Halpern et al., 2014), but there are indications that this tissue mediates cold as well as diet-induced thermogenesis in humans (as in mice and rats) (Vosselman et al., 2013a, b), and its lack or unresponsiveness under conditions of hypercaloric diet and overfeeding may explain a propensity towards easy weight gain (Stock, 1999; Vosselman et al., 2013b).

Oxidative capacity and uncoupling also have significant implications for white, unilocular adipocytes, especially in obesity, in terms of regulation of metabolic function, and glucose and fatty acid partitioning during both fasting and feed

Figure 1
Adipocytes export fatty acids during times of energy deficit (involved pathways are marked with green arrows). The rise in cAMP, a sign of increased glucagon or adrenergic stimulation, and low insulin stimulate hydrolysis of triglycerides into glycerol and fatty acids. The increased cAMP pool activates PKA that, in turn, phosphorylates hormone-sensitive lipase (HSL) and perilipins to increase lipolysis. Glycerol and fatty acids are mostly exported into the circulation for systemic utilization. A proportion of fatty acids is re-esterified within the adipocytes, while another part may, after activation to form acetyl-CoA, enter the mitochondria for β-oxidation through carnitine palmitoyl transferase-1 (CPT-1). This rate-limiting enzyme is inhibited by malonyl-CoA, an intermediate of de novo lipogenesis regulated by acetyl coenzyme A (ACC). ACC prevents the oxidation of fatty acids when adipocytes are in a lipogenic state. Inhibition of ACC by AMPK relieves this inhibition for β-oxidation. Under positive energy balance, insulin regulates glucose and fatty acid uptake in adipose tissue, and expression and activity of enzymes involved in their metabolism and deposition into TAG, that is, lipogenesis (marked by red arrows). In short, insulin through binding to its cell surface receptor stimulates tyrosine kinase activity, which phosphorylates key residues on several ‘docking proteins’, IRS proteins. Assembly of a stable complex leads to the regulation (in most cases, activation) of downstream signalling pathways. Recruited proteins include the p85 regulatory subunit of PI3-kinase, which stimulates signalling pathways ultimately leading to PI3-kinase-dependent serine/threonine PKAkt/PKB activation. Phosphorylation of Akt1 at two regulatory residues, Ser273 and Thr308, is critical for complete Akt/PKB activation in adipose tissue. Akt stimulates the translocation of the glucose transporter, GLUT4, to the plasma membrane, thereby promoting uptake of glucose into the cell. A high level of circulating insulin also stimulates PDE3B, promoting cAMP hydrolysis, lowering PKA activity and PKA-dependent HSL phosphorylation, activation and lipolysis. Chronic insulin signalling enhances cAMP production through β-adrenoceptor activation in adipocytes but also disrupts the signalling pathway between β-adrenoceptors and PKA. Imported as well as de novo synthesized fatty acids from excess glucose combine with CoA, and after successive esterification, form TAG. The (re)-esterification process requires production of glycerol-3-phosphate as a substrate for fatty acid re-esterification into TAG. Glycerol-3-phosphate is mostly derived from glucose in the fed state (glycolytic intermediates). Because the glucose supply to the tissue is limited in the fasting state (lipolytic stimulation) and adipocytes have no significant glycerol kinase activity, glycerol-3-phosphate is acquired from lactate or pyruvate.
During the fasting response, stimulation of $\beta$-oxidation in adipocytes may restrict high fatty acid export into the circulation and prevent or delay obesity development (Horowitz, 2001). In the fed state, adipocytes shift to glycolytic ATP production. Consequently, the levels of all metabolic products of glucose (CO$_2$ and pyruvate/lactate) increase up to 10-fold, along with adipocyte size (DiGirolamo et al., 1992). Intensified flux through the glycolysis and pentose phosphate pathway provides energy for adipocyte activity and directs excess metabolic substrates into TAG synthesis (lipogenesis) (DiGirolamo et al., 1992). Earlier, Rossmeisl et al. (2000) demonstrated that total uncoupling of OXPHOS in 3T3-L1 adipocytes induced by 2,4-dinitrophenol or ectopic UCP1 in white fat of transgenic aP2-UCP1 mice restricts in situ lipogenesis. Subsequent studies revealed that mitochondrial OXPHOS supports high energy-consuming processes, such as fatty acid storage, adipokine synthesis/secretion (Koh et al., 2007), insulin signalling and glucose uptake (Shi et al., 2008) and adipogenesis (Ryu et al., 2013), in differentiating 3T3-L1 adipocytes. Moreover, increased glucose and fatty acid flux/cycling through adipocytes occurring after treatment of adipocytes with insulin, corticosteroids, pro-inflammatory cytokines, lipid (Hoehn et al., 2009) or lactate (Carriere et al., 2014) or exposure of rats to the cold (Jankovic et al., 2015a), promote mitochondrial biogenesis and uncoupling. Besides increased energy dissipation and thermogenesis, these processes could be considered an adaptive stress response of adipocytes to the increased inflow of reducing equivalents to the mitochondrial ETC (Jeanson et al., 2015; Jankovic et al., 2015b). Thus, proper capacity for oxidation of glucose and fatty acids, OXPHOS, uncoupling and biogenesis of new mitochondria are indispensable in the daily metabolic regulation of adipocytes and long-term adipose tissue function and healthy expansion (Wilson-Fritch et al., 2004; De Pauw et al., 2009; Hao et al., 2010; Lu et al., 2010). In diabetes, the capacity of adipose tissue in energetic remodeling is impaired (Choo et al., 2006; Keller and Attie, 2010).

In addition to metabolic and cellular plasticity, healthy adipose tissue expansion requires normal blood flow and vascularity (Frayn et al., 2003) as well as hyperplastic potential, because these factors account for greater lipid-buffering capacity (Rutkowski et al., 2015). Conversely, pathological (unhealthy) expansion of adipose tissue is characterized by changes in blood flow and the presence of enlarged, dysfunctional, that is, insulin-resistant, adipocytes (see Lafontan, 2017).
Adipose tissue-specific insulin resistance (impaired glucose and fatty acid uptake and utilization) appears to be an early and irreversible defect that explains the causal relationship between adipocyte dysfunction and systemic insulin resistance (Loizzo, 2009; Lafontan, 2013). Hitherto, studies on animal models (mutant mice, diet-induced obesity) and cultures of mouse and human adipocytes have provided strong support for the involvement of hypoxia, inflammatory signalling, endoplasmic reticulum stress and unfolded protein response, autophagy, dysfunction of mitochondria/impaired mitochondrial biogenesis, and oxidative stress in the development of fat-specific insulin resistance (see Wood et al., 2009; Blüher, 2009; Netzer et al., 2015).

Temporal progression of oxidative damage in the pathogenesis of obesity and associated metabolic disorders is poorly understood, because the classical ‘markers’ of oxidative damage (oxidation products of lipids, DNA and proteins), in contrast to levels in plasma, urine and various non-adipose tissues, are only minimally increased in mouse (Furukawa et al., 2004; Garcia-Diaz et al., 2007; Grimsrud et al., 2007) and human (Frohnert et al., 2011; Jankovic et al., 2014) adipose tissues in obesity. The data suggest that the increase in superoxide and ROS/RNS levels in the mitochondria of expanding adipose tissue precedes adipocyte dysfunction and progression of obesity-related metabolic disorders in metabolically healthy control mice (Houstis et al., 2006; Matsuzawa-Nagata et al., 2008) and individuals (Jankovic et al., 2014). Notably, increased $O_2^{-}$ is a critical interfering factor in signalling of NO and other ROS/RNS essential for the lipid buffering function of adipose tissue, thus differentiating unhealthy from healthy expansion, that is, insulin-resistant from insulin-sensitive obesity (Sansbury and Hill, 2014).

**Biological effects of NO in adipose tissue**

NO, a gaseous signalling molecule similar to CO$_2$, CO, H$_2$S and O$_2$, is toxic at high levels but essential in the regulation of biological processes when endogenously produced in nM concentrations. The multifaceted role of NO in adipose tissue corresponds to the extremely complex mechanisms of biological effects that depend on its (i) site and level of production, determined by enzymes involved in NO synthesis and availability of their substrates and cofactors, and (ii) interactions with different cellular biotargets, primarily ferrous iron (haem and non-haem), thyl radicals, molecular oxygen and superoxide (Beckman and Koppenol, 1996; Wink and Mitchell, 1998).

**Endogenous production of NO in adipose tissue**

In virtually all cell types, NO is synthesized via NO$\text{-}$catalysed oxidation of l-arginine (Moncada et al., 1989). Basal eNOS (NOS3) and iNOS (NOS2) expressions have been reported in rat and human adipose tissue and adipocytes (Ribiere et al., 1996; Elizalde et al., 2000; Gaudiot et al., 2000). Neuronal NOS (nNOS, NOS1) protein does not appear to be present in significant amounts (Engeli et al., 2004), although some studies have provided evidence for protein expression of nNOS in the cytoplasm (Fu et al., 2005; Jobgen et al., 2006) and mitochondria (Finocchietto et al., 2011) of adipocytes. eNOS is mostly membrane bound, while iNOS is localized in the cytoplasm of adipocytes and macrophages (Jobgen et al., 2006). However, following post-translational modification and protein/protein interactions, NOS proteins translocate into different cellular compartments, leading to localized biological effects of NO and regulation of different signalling pathways (Giordano et al., 2002; Villanueva and Giulivi, 2010). Under most physiological conditions, eNOS and nNOS synthesize low levels of NO (nM), whereas iNOS expression is up-regulated by LPS, TNF-α and interferon-γ, leading to the generation of high levels of NO (μM) lasting for several hours or days (Stamler and Meissner, 2001; Pilon et al., 2004).

The reductive pathways, that is, synthesis of NO from nitrite (NO$_2^{-}$) catalysed by several transition metal-containing proteins, such as xanthine oxidoreductase (XO) (Zhang et al., 1998), deoxymyoglobin/deoxyaemoglobin (Nagabu et al., 2003), cytochrome c (Busu et al., 2008), complex III (Nohl et al., 2000), cytochrome c oxidase (CcOx) (Castello et al., 2006) or NO (Vanin et al., 2007), represent a relevant NO source in hypoxic and acidic intracellular micro-environments (Shiva, 2013; Sparacino-Watkins et al., 2014) after exercise (Cosby et al., 2003) or ischaemia/reperfusion injury and myocardial ischaemic conditioning (Shiva et al., 2007; also see Andreadou et al., 2015). A recent study by Roberts et al. (2015) showed that exposure of rats in vivo and primary adipocytes ex vivo to hypoxia augments nitrate-mediated NO production with subsequent up-regulation of brown adipocyte-associated genes. These authors suggested that augmentation of the nitrate-stimulated browning response during hypoxia represents a physiological adaptation of adipocytes undergoing hypertrophy in obesity. This NO-producing pathway may be exploited therapeutically to maintain oxidative capacity of adipocytes to metabolize fatty acids and to counteract the obesity-related pathological metabolic state of adipose tissue (Roberts, 2015).

**Interaction of NO with soluble guanylate cyclase (sGC) and cGMP-mediated signalling in adipocytes**

NO was initially identified as the first gaseous messenger molecule that acts through a completely novel mechanism, that is, binding to ferrous haem of sGC, leading to increased levels of the second messenger cGMP (Ignarro, 1990a, b). This NO-mediated mechanism covers a range of downstream signalling pathways in fundamental processes of virtually all cell types (Murad, 1988; Murad et al., 1990; Krumenacker and Murad, 2006), including adipocytes (Hemmrich et al., 2010). In adipose tissue, the reaction between NO and sGC, occurring at nM concentrations of NO (Bellamy and Garthwaite 2001; Rodriguez-Juarez et al., 2007), is mediated by constitutive eNOS. Recent data suggest that NO produced by the nitrite reductase activity of XO also acts through the sGC/cGMP signalling pathway (Roberts et al., 2015). Physiological levels of NO produced in adipose tissue regulate blood flow and vascularization in a sGC/cGMP-dependent manner, promoting substrate uptake and product removal via the circulation, thereby matching energy inflow/outflow with tissue perfusion (Jobgen et al., 2006). Additionally, endogenous NO directly mediates the metabolic response of adipocytes (see Jobgen et al., 2006, McKnight et al., 2010). First, physiological levels of NO stimulate the insulin-triggered (Roy et al., 1998) and (probably) insulin-independent uptake and oxidation of glucose (Tanaka
et al., 2003; Jobgen et al., 2006). The underlying molecular mechanisms of the latter involve sGC/cGMP-dependent stimulation of AMP-activated protein kinase (AMPK) through increasing gene expression and PKG-dependent AMPK phosphorylation (Jobgen et al., 2006). Second, NO stimulates lipid degradation (lipolysis) and β-oxidation through both AMPK-dependent and AMPK-independent mechanisms.

Upon activation by NO, AMPK phosphorylates and inactivates acetyl-CoA carboxylase, thereby reducing the conversion of acetyl-CoA to malonyl-CoA, which suppresses de novo fatty acid synthesis and activates carnitine palmitoyltransferase I, facilitating the transport and oxidation of fatty acids in mitochondria. NO also increases OXPHOS and mitochondriogenesis through an AMPK-mediated increase in PPARγ coactivator 1α (PGC-1α) expression (Tedesco et al., 2010). PGC-1α is the principal regulator of mitochondrial biogenesis and function. In combination with PPARγ, PGC-1α increases mtDNA replication, OXPHOS, mitochondrial fatty acid β-oxidation, UCP1 and mitochondrial antioxidant defense primarily in brown adipocytes (Bossy-Wetzel and Lipton, 2003; Kelly and Scarpulla, 2004) and possibly white adipocytes (Clementi and Nisoli, 2010). Through these pathways, NO supports healthy adipose tissue function, that is, long-term insulin sensitivity (Fu et al., 2005; Wu et al., 2007; Jobgen et al., 2009).

The groups of Fu et al., (2005) and Wu et al., (2007) showed that dietary supplementation with L-arginine, a substrate for NO synthesis, reduces body weight and fat mass in Zucker diabetic fatty rats. L-arginine induced a marked increase in expression of nNOS, haem oxygenase 3, AMPK and PGC-1α in white adipose tissue of Zucker diabetic fatty rats (Fu et al., 2005). In addition to stimulation of eNOS activity by high-dose L-arginine via direct administration, L-arginine can outcompete binding of the endogenous inhibitor of eNOS, asymmetric dimethyl-L-arginine, and force its removal from endothelial cells by driving the cationic amino acid transporter (Closs et al., 2012). Effects of NO on reducing fat mass may be attributed, in part, to the appearance of brown/brite adipocytes or brown-like phenotype (UCP1) in white adipocytes, that is, browning (Nisoli and Carruba, 2006; Joffin et al., 2015; Roberts et al., 2015). We recently showed that L-arginine enhances the cold exposure-induced UCP1 level in mitochondria of unilocular white adipocytes in rats. Moreover, a similar increase in UCP1 protein expression was observed in rats maintained at room temperature (presented in Figure 3).

The essential role of eNOS-synthesized NO at nM levels in the metabolic plasticity of adipose tissue was confirmed in studies showing that eNOS knockout mice exhibit decreased UCP1 and PPARγ expression, reduced number of mitochondria, defective energy expenditure, increased body weight, insulin resistance and hypertension (Nisoli et al., 2007). eNOS−/− mice displayed exaggerated high-fat diet-induced weight gain (Shankar et al., 2000; Duplain et al., 2001; Cook et al., 2003). Furthermore, eNOS expression was remarkably diminished in fat tissue in obese rodents (Valerio et al., 2006) and humans (Perez-Matute et al., 2009; Georgescu et al., 2011), while its overexpression prevented diet-induced obesity, increased metabolic activity and promoted brown adipose tissue-like phenotype in white adipose tissue in mice (Samsbury et al., 2012). Similarly, constitutive activation of eNOS by knocking in a phosphomimetic point mutation at Ser1176 was shown to promote resistance to diet-induced weight gain (Kashiwagi et al., 2013).

NO activates AMPK and its downstream pathways in a cGMP/PKG-dependent manner (Jobgen et al., 2006). Conversely, eNOS itself may be activated by AMPK. In endothelial cells, AMPK activates eNOS via phosphorylation at Ser1177 and Ser633 (Chen et al., 1999, 2009). The latter phosphorylation event is slower and Ca independent and serves to maintain NO synthesis after the initial increase in NO induced by

Figure 3
Appearance of UCP1 in the mitochondria of unilocular, white adipocyte in retroperitoneal white adipose tissue of rats maintained at room temperature after 3 days of L-arginine treatment. Light (A), electron (B) microscopy and immunogold (C) revealed the presence of UCP1 (arrows) in white adipocytes mitochondria. Bars: (A) 20, (B) 2 and (C) 1 μm.
Ser\textsuperscript{177} phosphorylation, owing to a positive feedback loop (Schulz \textit{et al.}, 2009). On the other hand, AMPK-mediated post-translational phosphorylation of iNOS inhibits its activity and enhances insulin sensitivity in adipose tissue (Pilon \textit{et al.}, 2004). Thus, regulation of AMPK by NO may play an important role in controlling the relative eNOS and iNOS activities, NO levels and effects on adipose tissue.

**Interaction of NO with CcOx: a potential key metabo-regulatory role in the postprandial response of adipocytes?**

In addition to the ferrous iron in sGC, NO interacts directly with several ferrous haem proteins in near-diffusion-limited reactions (k \times 10\textsuperscript{-9} M\textsuperscript{-1} s\textsuperscript{-1}). The most important of these is the reaction with CcOx, the terminal complex of the mitochondrial ETC. The NO–CcOx system helps to fine-tune cellular respiration (Brown, 1995) and metabolism (Semenza, 1999).

Increased expression of mitochondrial NOS (potentially nNOS) in adipocytes of ob/ob mice led to reduced oxygen uptake via inhibition of CcOx (Finocchietto \textit{et al.}, 2011). The presence of mitochondrial NOS in adipocytes (as in other cells) is disputable, but other NOS stimulated by insulin may have similar mitochondrial effects (Jezeck \textit{et al.}, 2010), because in adipocytes, insulin rapidly enhances NOS activity (Ribiére \textit{et al.}, 2002; Engeli \textit{et al.}, 2004) as in endothelial cells (Dimmeler \textit{et al.}, 1999). Moreover, eNOS relocalizes upon post-transcriptional modification, that is, attaching to the outer mitochondrial membrane, at least in neurons and endothelial cells (Henrich \textit{et al.}, 2002; Gao \textit{et al.}, 2004). This finding indicates that eNOS regulates mitochondrial function, and conversely, mitochondria regulate eNOS activity (Nisoli and Carruba, 2006). Accordingly, NO synthesized by eNOS may transiently bind to CcOx and inhibit respiration under appropriate stimulation (e.g. by insulin) (Brown, 2001). This may induce a type of ‘metabolic hypoxia’, a phenomenon that restricts oxygen utilization (Moncada and Erusalinsky, 2002), that is, glucose oxidation. In postprandial adipocytes, ‘metabolic hypoxia’ may switch the cell to the glycolytic mode of ATP production and redirect glucose into lipids, similar to mtNOS-derived NO in muscle cells, in response to insulin (Finocchietto \textit{et al.}, 2008). Overexpression of nNOS or iNOS may contribute to ETC inhibition, oxygen uptake inhibition, mitochondrial dysregulation and insulin resistance progression in prediabetic states via the same mechanism (see Jezeck \textit{et al.}, 2010).

**Interaction of NO with oxygen and thiols**

NO also binds to oxygen and thyl radicals, especially at \textmu M levels. Reaction of NO with O\textsubscript{2}, resulting in N\textsubscript{2}O\textsubscript{3} or NO\textsubscript{2}, may further cause S-oxidation and S-nitrosylation (S-nitrosation) of protein side chains (Stamler \textit{et al.}, 1992; Stamler, 1995; Beltrán \textit{et al.}, 2000; Hess \textit{et al.}, 2001). Moreover, these reactions may occur by direct covalent binding of NO with cysteinyl thiols of GSH and proteins upon transfer of NO\textsuperscript{+} from S-nitrosothiol (SNO). S-nitrosothioglutathione contributes to preservation of cellular NO activity as a delayed donor of NO. S-nitrosothioglutathione and protein CysNO may subsequently react with GSH to generate a mixed disulphide and promote the release of HNO, another vasodilator. Such \textit{trans}-S-nitrosation reactions within cells facilitate redistribution of NO among different -SNO pools (Liu \textit{et al.}, 1998; Yang and Loscalzo, 2005).

Protein Cys residues are capable of oscillating between reduced (–SH) and different oxidized states, including thiolate anion (–S\textsuperscript{-}), sulphenate (–SO\textsuperscript{2-}), disulphide (–S–S–), sulphinate (–SO\textsuperscript{3-}) or sulphonate (–SO\textsubscript{4}–). Among these, the latter two are considered irreversible oxidative modifications in mammalian cells (Jones, 2008). The redox state of the sulphur atom within Cys in the catalytic (regulatory or binding) domain of proteins may alter activity. In the biological context, oxidation and nitrosation reactions are compared with phosphorylation/dephosphorylation as the second prototypic post-translation mechanisms leading to redox regulation of protein activity/function (Lane \textit{et al.}, 2001).

In adipocytes, as in most cells, S-nitrosation of mitochondrial ETC thiol groups (especially complexes I and II) may slow down respiration (Moncada and Erusalinsky, 2002), acting synergistically in the transient inhibition of CcOx via NO binding. Both processes play an important role in the regulation of glycolytic (i.e. lipogenic) mode of postprandial adipocytes (Jezeck \textit{et al.}, 2010).

Moreover, transient S-oxidation/S-nitrosation is indispensable in the maintenance of normal insulin signalling in adipocytes. Under normal (unstimulated or basal) circumstances, most protein Cys residues are maintained in the reduced state due to high levels and overall presence (cytoplasmic and mitochondrial) of GSH and thioredoxins (Trx), peroxiredoxins and the corresponding NADPH-coupled reductase systems (Fisher-Wellman and Neufer, 2012). This sets up a ‘basal’ phosphate tone in unstimulated adipocytes, because protein phosphatases, particularly protein tyrosine phosphatases (PTPs) and the phosphoprotein phosphatase family of Ser/Thr phosphatases, are active under reduced conditions (Chiarugi, 2005; Wright \textit{et al.}, 2009; Fisher-Wellman and Neufer, 2012). However, a small shift in the redox state to pro-oxidative conditions, for example, due to insulin-mediated increase in ROS/RNS, promotes S-oxidation/S-nitrosylation of Cys in different proteins, such as protein kinases and phosphatases involved in insulin signalling. ROS/RNS play a superimposing role by controlling the phosphorylation state of proteins in the insulin signalling cascade via reversible S-oxidation/S-nitrosylation of PTPs, and their reactivity may therefore lead to changes in insulin sensitivity in adipose tissue. Moreover, NO-induced S-nitrosylation at the active site Cys residue of PTPs (SHP-1, SHP-2 and PTP1B), concomitant with eNOS-mediated NO burst in response to insulin action, supports NO-dependent regulation of tyrosine phosphorylation of the insulin receptor and its downstream effector kinases, insulin receptor substrate 1 (IRS-1) and PKB/Akt, at least in mouse endothelial MS-1 cells (Hsu and Meng, 2010). It is tempting to speculate that NO plays important permissive roles for transmission of the insulin signal in adipocytes also, via similar mechanisms.

**Interaction of NO with superoxide**

Within all the molecular targets of NO in the cell, superoxide is the most critical intervening factor of its biological effects, especially in the presence of high levels of NO. At equimolar
Targeting NO/superoxide ratio in obesity

British Journal of Pharmacology (2017) 174 1570–1590

concentrations, these two reactive species combine at a diffusion-limited rate \((k \approx 10^8 \text{ to } 10^{10} \text{ M}^{-1}\text{s}^{-1})\) that exceeds the reactions of NO with all other biotargets (iron, thiols and oxygen) and the reaction velocity upon combination with superoxide dismutase (SOD) \((k \approx 10^7 \text{ M}^{-1}\text{s}^{-1})\), changing the biological action of NO and other ROS/RNS under oxidative stress conditions (Koppenol et al., 1992; Koppenol, 2001). The balance between local concentrations of NO, \(\text{O}_2^\cdot\) and SOD is important in determining the effects of the NO/superoxide radical pair (Beckman and Koppenol, 1996; Rubbo et al., 1996). No significant competition occurs between NO and SOD for \(\text{O}_2^\cdot\) under normal physiological conditions, because NO is in the nM range, compared with \(\mu\text{M}\) levels of SOD in cells. Under physiological conditions, reaction of \(\text{O}_2^\cdot\) with NO constitutes only a minor part of the dismutation reaction of \(\text{O}_2^\cdot\) by SOD. As a result, very little peroxynitrite \((\text{ONOO}^\cdot)\) is formed (Ferdinand and Schulz, 2003). However, at increased rates of NO production (possibly via iNOS expression), when the levels of NO are \(\geq 1 \mu\text{M}\), \(\text{ONOO}^\cdot\) formation predominates over dismutation of \(\text{O}_2^\cdot\) (Depre and Hue, 1994; Csonka et al., 1999; Ferdinandy et al., 2000). Additionally, the increase in \(\text{O}_2^\cdot\) levels due to increased production and/or decreased dismutation may lead to an effective increase in the probability of \(\text{ONOO}^\cdot\) formation. Both prerequisites, iNOS-mediated NO production and increase in superoxide levels, occur in adipose tissue under conditions of obesity.

**Adipose tissue in the obese state: the paradigm of NO/superoxide interactions**

As mentioned previously, decreased NO bioavailability is a sign of early risk of fat-specific insulin resistance development in obesity, and increased superoxide level in accumulating adipose tissue is the key factor in the initiation and progression of fat-specific insulin resistance. *Inter alia*, high \(\text{O}_2^\cdot\) and NO levels are characteristic of adipose tissue in obesity. \(\text{O}_2^\cdot\) antagonizes the direct effects of NO, and \(\text{ONOO}^\cdot\) formation and/or derived ROS/RNS can alter cell signalling, in part, by promoting oxidation, nitrosylation or nitration of a broad range of proteins, including enzymes of intermediary metabolism, mitochondrial complexes and insulin signalling.

**Sources of high superoxide in obesity: antagonists of physiological NO functions**

Superoxide in adipose tissue is primarily generated by overloading the mitochondrial OXPHOS system with metabolites from glucose, fatty acids and NOXs (Han et al., 2012). In recent years, eNOS uncoupling has been recognized as an important superoxide source in various tissues in obesity (Margaritis et al., 2013; Yu et al., 2014). XO, an enzyme that catalyses the conversion of hypoxanthine to uric acid and \(\text{O}_2^\cdot\), has been proposed to play a critical role in superoxide production in mature adipocytes (Furukawa et al., 2004). Although hyperuricaemia has been linked to metabolic syndrome, the role of XO in adipose tissue as the source of superoxide remains poorly understood. The enzyme may be of importance, especially in impairment of adipose tissue blood flow, because pro-inflammatory cytokines irreversibly convert endothelial xanthine dehydrogenase to the oxidase form, XO (Vorbach et al., 2003).

**Enhanced production of superoxide by mitochondria.** During respiration, a significant proportion of oxygen molecules are incompletely converted to \(\text{H}_2\text{O}\) and end up as \(\text{O}_2^\cdot\) via a non-enzymatic pathway, owing to electron leak from complexes I and III of the ETC (Turrens and Boveris, 1980). Mitochondrial \(\text{O}_2^\cdot\) is linked to hyperglycaemia-induced metabolic dysfunction in endothelial cell systems (Brownlee, 2001) and inflammation in adipocytes (Lin et al., 2005). A recent study showed that overfeeding (and/or high-calorie intake) increases the reduced state of electron carriers in the ETC and subsequently the probability of electron extraction by high reduction potential molecules, such as molecular oxygen (to create \(\text{O}_2^\cdot\)) (Matsuzawa-Nagata et al., 2008). This series of events is more evident in hyperglycaemia. When the elevated carbohydrate fuel supply exceeds the metabolic needs of the cell, reducing equivalents (NADH) are overproduced (Frizzell et al., 2012). A dramatic increase in NADH exceeds the electron acceptor capacity of ETC complexes, thereby perpetuating electron leak and subsequent \(\text{O}_2^\cdot\) generation.

NOX. Superoxide/\(\text{H}_2\text{O}_2\) originating from NOX produced transiently in response to insulin stimulation acts as a second messenger for insulin signalling in adipocytes (Krieger-Brauer and Kather, 1992, 1995), while excessive and long-term activation of NOX reduces insulin sensitivity (Furukawa et al., 2004). NOX is a membrane-associated multimeric oxidoreductase that transports electrons preferentially from cytosolic NADPH (although nonphagocytic NOX, especially the NOX1 isoform, may also use NADH as substrate) down to the electrochemical gradient through the membrane to oxygen, generating \(\text{O}_2^\cdot\) that is rapidly converted to \(\text{H}_2\text{O}_2\) (Griendling et al., 2000). Among the seven isoforms of the catalytic subunit gp91phox of NOX, phagocytic NOX2 and NOX4 are present in adipose tissue, especially in resident macrophages and adipocytes (Mouche et al., 2007). NOXs are significantly increased in adipose tissue in different genetic and diet-induced models of obesity in rats (Furukawa et al., 2004) and humans (Jankovic et al., 2014). Moreover, a higher gp91phox protein level in visceral fat characterizes subjects with increased risk factors for metabolic syndrome, compared with metabolically healthy weight-matched subjects (Jankovic et al., 2014).

NOX4 generates \(\text{H}_2\text{O}_2\) even under basal conditions (via constitutive expression) (Nisimoto et al., 2010). Insulin and some anabolic hormones induce a several-fold increase in \(\text{H}_2\text{O}_2\) levels and expression of NOX4 (Goldstein et al., 2005). Increased oxidative state can lead to immune cell activation (Schulz et al., 2014; Kröller-Schön et al., 2014). In particular, excess glucose and palmitate generate ROS via a mechanism that involves translocation of NOX4 into lipid rafts of adipocytes, leading to expression of monocyte chemotactic factors (Yeop Han et al., 2010; Han et al., 2012). Conversely, inflammatory cytokines and NOX2-mediated ROS originating from activated macrophages may be involved in augmentation of adipocyte NOX4 and consequent ROS production in obese adipose tissue (Furukawa et al., 2004). Possibly,
complex crosstalk of adipocyte and macrophage NOXs establishes a vicious cycle that augments superoxide production in adipose tissue in obesity and diabetes (recently reviewed in Karbach et al., 2014, and Jankovic et al., 2015b).

Enhanced production of superoxide through eNOS uncoupling. In the absence of the coenzyme tetrahydrobiopterin (BH₄), NOS reduces molecular oxygen, rather than L-arginine, resulting in production of superoxide rather than NO, a phenomenon known as ‘NOS uncoupling’ (Münzel et al., 2008). Several hypotheses have been proposed for intracellular BH₄ depletion, including ONOO⁻-mediated oxidation. Moreover, activation of the superoxide source (uncoupled eNOS) may stimulate the formation of superoxide and/or ONOO⁻ in a positive feedback manner, in turn, oxidising BH₄ to the BH₃ radical, leading to further ROS/RNS formation (Kuzkaya et al., 2003). eNOS dysfunction was observed under conditions of oxidative stress and inflammation in perivascular adipose tissue (Filip et al., 2012; Margaritis et al., 2013). Increased superoxide production by uncoupling of eNOS is recognized as an important factor that decreases the vasodilatory role of perivascular adipose tissue in obesity. During early diet-induced obesity, adaptive overproduction of NO occurs in perivascular adipose tissue, while in established obesity, perivascular adipose tissue loses its vasodilatory properties via an increase in ‘contractile’ superoxide, leading to endothelial dysfunction and vascular disease (Fernandez-Alfonso et al., 2013). Increased nitro-oxidative pressure seen in perivascular adipose tissue in obesity may also occur in other adipose tissue areas. In fact, this may be critical for the impairment of blood flow, tissue oxygen and substrate supply in adipose tissues in obesity (see Alemany, 2012).

Lower antioxidant defence mechanisms. To prevent ROS/RNS excess, cells are equipped with antioxidant enzymes, such as manganese SOD (MnSOD), in the mitochondrial matrix and copper, zinc SOD in the cytosol and intermembrane space of mitochondria, which convert O₂⁻ into H₂O₂ (Fridovich, 1995). H₂O₂ is further reduced to H₂O by catalase, GSH peroxidase and Trx/peroxiredoxin systems. GSH and Trx reduce peroxide concentrations and protein disulphide, subsequently producing oxidized GSH and Trx respectively. Oxidized GSH and Trx are converted back to reduced GSH, that is, Trx, via NADPH-dependent reductases, respectively, thus maintaining the reduced cellular redox state (Halliwell and Gutteridge, 2007). NADPH, the reducing power for GSH (Cys) and Trx recycling, is provided by the pentose phosphate pathway and malic enzyme.

Accordingly, lower SOD levels may contribute to increased superoxide and thus higher probability of ONOO⁻ formation in the metabolic syndrome. Likewise, the mitochondrial antioxidant enzymes, MnSOD and GSH peroxidase, show decreased activity in adipose tissue, with the most pronounced decline in obese type 2 diabetic subjects and, to a lesser degree, non-obese type 2 diabetic or non-diabetic obese subjects (Chattopadhyay et al., 2015). Consistent with these findings, our group showed that SOD levels were not significantly decreased in obese, insulin-sensitive subjects, while a significant decrease in SOD activity and MnSOD protein expression, in addition to lower levels of GSH, characterized visceral adipose tissue of subjects with increased cardiometabolic risk factors (Jankovic et al., 2014).

Besides conventional antioxidant mechanisms, uncoupling capacity plays a significant role in determining superoxide production from ETC. Uncoupling decreases the pressure on ETC complexes and increases electron transfer capability, thereby suppressing the leak of electrons and subsequent production of O₂⁻. UCP1 gene expression is undetectable in adipogenic precursor cells isolated from lean and obese individuals from subcutaneous abdominal white adipose tissue biopsies. However, after adipocyte differentiation, both gene expression and protein content of UCP1 are increased. UCP1 levels are significantly greater in cultures from lean, compared with obese individuals (Carey et al., 2014). Moreover, morbidly obese subjects express significantly lower levels of UCP mRNA than lean controls (Oberkofler et al., 1997). In parallel, fat mitochondria from obese type 2 diabetic subjects produce considerably more ROS, compared with those of controls and non-diabetic subjects. In the majority of cells, including adipocytes, the antioxidant role is mainly attributed to UCP2. However, recent data indicate that a short-term UCP1 increase may buffer the reductive pressure on mitochondrial ETC and consequent oxidative pressure in white adipocytes (Jankovic et al., 2015b). In addition, both uncoupling agents and MnSOD mimics that alleviate the O₂⁻ level in the ETC rapidly restore the insulin sensitivity of adipocytes (Hoehn et al., 2009). Thus, the antioxidant role of mitochondrial UCPs is important during adipocyte differentiation and their response to overfeeding, and its impairment may contribute to higher mitochondrial superoxide release. Moreover, reduction in mitochondrial number without concomitant reduction in nutrient uptake leads to an increase in net substrate flux through the remaining mitochondria and subsequent O₂⁻ production (Hoehn et al., 2009). Thus, lower or impaired mitochondrial potential may also contribute to increased superoxide levels in persistent overfeeding.

iNOS in obesity and insulin resistance

iNOS⁻/⁻ mice are protected from high-fat diet-induced insulin resistance. While wild-type and iNOS⁻/⁻ mice on a high-fat diet develop obesity, obese iNOS⁻/⁻ mice exhibit improved glucose tolerance, normal insulin sensitivity in vivo and normal insulin-stimulated glucose uptake in muscles. iNOS is increased in fat of genetic and dietary (high-fat feeding) models of obesity (Perreault and Marette, 2001). Chronic NO synthesis by iNOS represents an important contributory factor to nitrosative stress and development of fat-specific insulin resistance (Kaneki et al., 2007). In adipose tissue, the majority of iNOS is derived from phenotypic transformation of anti-inflammatory ‘alternatively activated’ macrophages to a more pro-inflammatory ‘classically activated’ form (Weisberg et al., 2003; Lumeng et al., 2007). In addition, high levels of TNF-α in adipocytes induce increased iNOS expression (Merial et al., 2000). Almost any factor that...
Effects of interaction of NO with superoxide in adipose tissue in obesity

Interactions between NO and superoxide and the consequent effects in vivo are very complex, because they depend not only on the relative levels of reactants and kinetics but also on spatial (where) and temporal (at the same time) prerequisites. In contrast to NO that may act as either an intracellular or intercellular messenger, the half-life of superoxide is mainly restricted by SODs, and therefore, interactions most likely occur at the sites of superoxide production. In adipocytes, mitochondria and NOX4 enzyme localized in the cellular plasma membrane and intracellular membranous structures represent the major sites of NO/superoxide interactions (Bedard and Krause, 2007). This may also explain why the major burden of S-nitrosated/nitrated proteins is found in these compartments.

Finally, ONOO\(^-\), the product of NO/superoxide interactions, exists as peroxynitrous acid (ONOOH) at physiological pH that is prone to proton-catalysed and carbon dioxide-catalysed homolysis, generating even more potent oxidants, such as hydroxyl (\(^{\cdot}\)OH), nitrogen dioxide (NO\(^2\)\(^+\)) and carbonate anion (CO\(_3\)\(^2-\)) radicals, which induce oxidation, nitrosation or nitration of protein side chains (see Toledo and Augusto, 2012). Protein modification by tyrosine nitration is mainly attributable to ONOO\(^-\) (Ischiropoulos et al., 1992). The reversibility of tyrosine nitration by denitrases (Kamisaki et al., 1998; Irie et al., 2003) and proteolysis (and re-synthesis of nitrated proteins) (Souza et al., 2000) has altered the mainly negative perception of nitration and ONOO\(^-\). Accumulating data indicate that this protein modification plays an adaptive role in specific settings (Ferdinandy and Schulz, 2003), and the target proteins and extent of modification determine the resulting patho/physiological effects (Koeck et al., 2005, 2009). Extensive nitration of tyrosine residues in proteins is the fingerprint of different pathophysiological conditions, including the diabetic state (Koeck et al., 2009; Zhou et al., 2009; Charbonneau and Marette, 2010; Pilon et al., 2010).

All aspects of NO and superoxide interactions should be taken into account to explain why the higher production rate of NO and superoxide usually contributes to pathological conditions but also plays an adaptive role. This is very challenging when considering adipose tissue in obesity whose expansion is associated with pathologies but per se represents the adaptive response of tissue (schematically presented in Figure 4).

The literature shows that the level of endogenously formed ONOO\(^-\) increases in adipose tissue mainly as a result of hyperglycaemia, that is, established diabetes (Koeck et al., 2009). A similar increase in the ONOO\(^-\) level in diabetic hearts has been reported (Pechánová et al., 2015; Varga et al., 2015). In these circumstances, increased signalling through advanced glycation end products or their corresponding receptors (RAGE) may additionally lead to excessive superoxide formation and ONOO\(^-\) increase. Once formed, ONOO\(^-\) triggers a vicious cycle, further decreasing NO bioavailability and increasing nitro-oxidative stress. Using different mechanisms, ONOO\(^-\) may oxidize and decrease eNOS-mediated NO production and divert direct sGC-mediated and CcOx-mediated bioeffects of NO in adipocytes, including insulin sensitivity and mitochondrial number and function (through low PGC-1\(\alpha\) activation and/or expression – biogenic, OXPHOS and antioxidant capacity of mitochondria). In addition, ONOO\(^-\) may increase superoxide generation (again via eNOS and/or iNOS uncoupling, although the latter has not been confirmed for adipose tissue) and decrease superoxide neutralization (via nitration of MnSOD) and the pool of GSH. The latter parameters are initially increased in obesity as a compensatory response to increased levels of superoxide, SNO and ONOO\(^-\). The diminished antioxidant capacity of adipocytes (initially mitochondrial and subsequently cytosolic) renders more proteins susceptible to oxidation and nitration, resulting in inactivation or dysfunction. However, the important issue of which of these multiple effects represents an early event in ONOO\(^-\)-mediated toxicity at a time point prior to the onset of irreversible functional changes and insulin resistance in adipocytes remains to be resolved.

Nitro-oxidative state and insulin signalling/sensitivity

A number of researchers are currently investigating the pathways with potential ONOO\(^-\) involvement in relation to insulin signalling and resistance. Growing evidence suggests that tyrosine nitration can alter protein function by preventing functional phosphorylation (Mondoro et al., 1997; Rawlingson et al., 2003; Kaneki et al., 2007; Stadler, 2011). Hepatic insulin resistance in lipid-challenged mice results from ONOO\(^-\)-mediated tyrosine nitration of insulin receptor (IR)\(\beta\) and IRS-1/2 (which promotes inhibitory serine phosphorylation of IRS proteins) and Akt, directly inhibiting insulin signalling (Charbonneau and Marette, 2010). In addition, ONOO\(^-\) mediates muscle insulin resistance via nitration of IR\(\beta\)/IRS-1 and Akt (Zhou and Huang, 2009), while targeted disruption of iNOS reverses high-fat diet-induced impairment of the insulin-stimulated tyrosine phosphorylation of IR, IRS-1 and IRS-1-associated PI3K activity, Akt and insulin resistance in muscle of mice (Perreault and Marette, 2001). Yasukawa et al. (2005) reported that a similar mechanism of ONOO\(^-\)-mediated nitration may contribute to insulin resistance in adipocyte tissue. The group showed that pretreatment of cultured mouse 3T3-L1 adipocytes with the NO donor, S-nitroso-N-acetylpenicillamine, inhibits insulin-stimulated Akt/PI3K activation. Activation of the renin–angiotensin–aldosterone system plays an important role in cardiovascular complications in metabolic syndrome, and angiotensin II is a strong trigger of tyrosine nitration and inactivation of kinases involved in insulin signalling (Csibi et al., 2010).

The data of Nomiyama et al. (2004) showed that constitutive production of ONOO\(^-\) by the NO/O\(_2\)\(^-\) donor –3-(4-morpholinyl) sydnonimine hydrochloride (SIN-1) – dose-dependently inhibited insulin-stimulated glucose uptake in rat-1 fibroblasts expressing human insulin receptors. SIN-1 reduced the IRS-1 protein level, and IRS-1-associated PI3K activity through tyrosine nitration of at least four tyrosine residues, including Tyr\(^{1217}\), which is critical for the association of IRS-1 with PI3K.

A continuous consumption of surplus of nutrients also increased tyrosine nitration in adipocytes (Koeck et al., 2009). Moreover, the extent of tyrosine nitration and the cellular nitroproteome profile in adipocytes reflects rise in the glucose
concentration during continuous exposure, as well as during the periodic fluctuation in the more physiological glucose concentration (Koeck et al., 2009). The nitrated proteins in glucose-overloaded adipocytes are primarily those involved in glucose metabolism – glycolysis pathway and citric acid cycle (aldolase A, glyceraldehyde 3-phosphate dehydrogenase, etc.).

Figure 4
Interaction of NO and superoxide in the physiology and pathophysiology of adipose tissue. FA, fatty acid.
phosphoglycerate kinase, malate dehydrogenase, aconitase). Besides, increased nitration of some of the enzymes involved in lipid trafficking/oxidation contributes to insulin resistance in adipocytes. For example, both functionally important tyrosine residues (Tyr19 and Tyr128) in fatty acid binding protein 4 are found to nitrate in adipocytes exposed to high metabolic load (Koeck et al., 2009). The nitration of fatty acid binding protein 4 may affect its interaction with hormone-sensitive lipase (Adida and Sperner, 2006), translocation into the nucleus and interaction with PPARγ (Smith et al., 2007), which, in turn, may additionally down-regulate all PPARγ-mediated metabolic effects in adipose tissue, including insulin sensitivity (Koeck et al., 2009).

In contrast to these in vitro data, the evidence of high endogenous ONOO− levels and activity, primarily tyrosine nitration, in adipose tissue in obese or prediabetic animal models or humans is rather scarce. The reason may be that tyrosine nitration is a highly selective process limited to specific tyrosine residues on a surprisingly small number of proteins (Aulak et al., 2001; Gow et al., 2004; Kanski et al., 2005) and is thus detectable only at high ONOO− levels that mainly characterize already established diabetic conditions, as stated above.

Nevertheless, increased total protein S-nitrosylation, an alternative sign of ONOO− acting, has been detected in intra-abdominal adipose tissue of obese humans and high fat-fed or leptin-deficient ob/ob mice (Ovadia et al., 2011). Importantly, Yin et al. (2015) recently revealed the role of increased S-nitrosylation as the mechanism that links obesity-associated inflammation, lower PPARγ activity and insulin resistance in adipose tissue. They found that iNOS-mediated increase of nitro-oxidative stress translates from macrophages to adipocytes leading to S-nitrosylation of PPARγ on Cys1040. This in turn potentiates proteasomal degradation of PPARγ, decreasing its transcriptional function. Moreover, expression level of the main PPARγ-regulated insulin-sensitizing adipokine, adiponectin, was also lower as a result of increased S-nitrosylation of PPARγ (Yin et al., 2015). Similar results were observed in vivo, in visceral adipose tissue of obese diabetic db/db mice (Yin et al., 2015).

**Nitro-oxidative state and mitochondrial dysfunction**

Disruption of mitochondrial function is implicated in fat-specific insulin resistance. Many mitochondrial proteins, including the enzymes involved in fat oxidation and energy supply, could be oxidized/nitrated under increased nitro-oxidative pressure, leading to depletion of ATP and impairment of lipid-buffering capacity in diabetic adipose tissue in obesity. The half-life of ONOO− under cellular conditions is short (~less than 1 s), but sufficient to cross biological membranes. Thus, ONOO− or peroxynitrous acid may enter mitochondria from the cytosol or be directly produced within mitochondria. Indeed, persistent hyperinsulinaemia and nNOS/mtNOS activation may contribute to mitochondrial dysfunction and insulin resistance of adipocytes (Jezek et al., 2010; Finocchietto et al., 2011). A remarkable increase in nNOS activity and NO level in mitochondria of ob/ob adipocytes inhibits CcOX and cause intense nitration at complex I impeding subsequent electron transfer from NADH (Finocchietto et al., 2011). Recurrent nitrosative stress of progressively higher intensity and duration would lead to parallel oxidative stress due to corresponding shifts in respiratory chain redox states that stimulate O2− formation. In fact, according to the ‘Poderoso hypothesis’, accumulating oxidative/nitrosative stress in mitochondria of fat cells could lead to retrograde modulation of the insulin signalling pathway and therefore represents the basis of type 2 diabetes aetiology (Jezek et al., 2010).

**Nitro-oxidative state and lipolysis/re-esterification dysregulation**

As stated, nM levels of NO stimulate cAMP and PKA/hormone-sensitive lipase signalling, that is, lipolysis (Gaudiot et al., 2000; Jobgen et al., 2006), and decreased eNOS-mediated lipolysis could favour the development of obesity through retention of TAG within adipocytes. However, in obesity, diminished lipolysis can also be viewed as a mechanism limiting excessive fatty acid release and alleviating the development of insulin resistance and metabolic abnormalities (Girousse et al., 2013). Notably, impaired anti-lipolytic effects of insulin in the postprandial period could restrict fatty acid esterification in adipocytes, exposing non-adipose tissue to lipotoxicity. Recent studies have revealed that reduction in lipolysis improves glucose incorporation into adipocyte lipids without increasing fat mass (Girousse et al., 2013). Because high NO levels inhibit basal as well as catecholamine-stimulated lipolysis (Gaudiot et al., 1998; Andersson et al., 1999; Klatt et al., 2000), iNOS-mediated increase in NO in adipose tissue under insulin stimulation is considered an important regulator of the lipogenic function of postprandial adipocytes (Engel et al., 2004). However, recent data indicate that, in obesity, iNOS may, in fact, impair anti-lipolytic regulation in postprandial adipocytes, possibly via increased nitro-oxidative pressure. Specifically, iNOS increases S-nitrosylation of PKB/Akt and cAMP PDE (PDE3B). S-nitrosylation of PDE3B at Cys768 and Cys1040 (Ovadia et al., 2011) inhibits its cAMP hydrolytic activity (Zmuda-Trzebiatowska et al., 2007). The main metabolic consequence of increased S-nitrosylation and inactivation of Akt/PDE3B axis in adipose tissue in obesity is impairment of insulin-induced anti-lipolysis (Ovadia et al., 2011).

In addition to uncontrolled lipolysis, a high fatty acid output from adipose tissue leading to lipotoxicity and insulin resistance may result from impaired fatty acids re-esterification. This metabolic pathway requires glycerol-3P synthesis, a pathway relying on the activity of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C). Niang et al. (2011) and Jaubert et al. (2012) showed that long-term leptin treatment inhibits PEPCK-C by increasing iNOS-mediated PEPCK-C nitration, therefore limiting fatty acid re-esterification in rat adipocytes. The increased nitration of PEPCK-C by leptin may initially play beneficial role in obesity setting, by increasing energy expenditure (Jaubert et al., 2012). Nevertheless, in the long-standing hyperleptinaemic obesity increased nitration of PEPCK-C may restrict glyceroneogenesis, essential in the lipid buffering function of adipose tissue, ultimately leading to lipotoxicity.
Nitro-oxidative state and endoplasmic reticulum stress

The endoplasmic reticulum is essential for the folding and trafficking of proteins that enter the secretory pathway. The accumulation of misfolded or unfolded proteins in this organelle, known as endoplasmic reticulum stress, is a common pathogenic molecular mechanism underlying adipocyte-specific insulin resistance (Kawasaki et al., 2012; Boden et al., 2014). It has been recently shown in both genetic (ob/ob) and dietary (high-fat diet-induced) models of obesity that, in the setting of obesity, inflammatory input through increased iNOS-mediated S-nitrosylation and impaired splicing activity of a key regulator of adaptive unfolded protein response – inositol-requiring protein 1 – leads to impaired endoplasmic reticulum function (Yang et al., 2015). These data were obtained with liver tissue, but it could be assumed that increased

S-nitrosylation of the important proteins mediating unfolded protein response exists in adipose tissue in obesity. In support of this, injection of mice with a SOD mimetic (Mn (iii)tetrakis(4-benzoic acid) porphyrin) attenuated the induction of the unfolded protein response (Malhotra et al., 2008), while inhibition of iNOS reversed palmitate-induced endoplasmic reticulum stress response in 3T3-L1 adipocytes (Jeon et al., 2012).

Nitro-oxidative stress versus endogenous antioxidant defence

In addition to protein-bound thiols, ONOO⁻ can oxidize GSH (Villa et al., 1994; Mayer et al., 1995; Prendergast et al., 1997). GSH is an efficient endogenous scavenger of ONOO⁻ and plays a major role in cellular defense against this species. Thus, in the long term, exhaustion of GSH may



| Table 1 | Potential therapeutic strategies to improve fat-specific insulin sensitivity by targeting NO/superoxide ratio in adipose tissue |
|---|---|
| **Strategy (treatment)** | **Molecular mechanisms** | **Target cells and effects** | **References** |
| Exercise training and hypoglycemic agents | ↓ Uncoupling of eNOS, ↑ SOD, ↓ NOX activity | Endothelial cells; ↑ mitochondrial function | Shen, 2010 |
| Caloric restriction mimics (resveratrol) | ↑ eNOS, ↑ mitochondrial biogenesis factors | Endothelial cells; ↑ mitochondrial function | Rivera et al., 2009; Csizsar et al., 2009 |
| Statins, angiotensin-converting enzyme inhibitors, AT₁ receptor blockers or β-blocker - nebivolol | ↑ NO production, ↓ superoxide production | Endothelial cells and adipocytes; ↑ mitochondrial function | Münzel and Gori, 2009; Münzel et al., 2010; Huang et al., 2013 |
| BH₄, BH₄ precursor (sepiapterin) | ↓ Uncoupling of eNOS, ↑ NO production, ↓ superoxide | Endothelial cells; ↑ mitochondrial function and insulin sensitivity | Heitzer et al., 2000; Schulz et al., 2008 |
| Folate | ↓ Uncoupling of eNOS, ↑ NO production, ↓ superoxide | Endothelial cells; ↑ mitochondrial function and insulin sensitivity | Verhaar et al., 2002 |
| Coenzyme Q10 | ↓ Superoxide production | Adipocytes and other cells; ↑ mitochondrial function, ↓ inflammatory process and lipid-metabolizing effects | Alam and Rahman, 2014 |
| Curcumin | ↓ Superoxide and NO overproduction | Adipocytes and other cells; protecting mitochondria and ↓ inflammation | Martínez-Morua et al., 2013; Priyanka et al., 2014a |
| Bilobalide | ↓ Superoxide production, ↑ SOD | Adipocytes; protecting mitochondria and ↓ inflammation | Priyanka et al., 2014b |
| Mitochondria-targeting SOD mimetics | ↓ mitochondrial superoxide production | Adipocytes; ↑ insulin sensitivity | Hoehn et al., 2009 |
| Lipoamide or lipoic acid | ↑ eNOS–cGMP–PKG pathway; biogenesis of mitochondria | Adipocytes; ↑ mitochondrial function and insulin sensitivity | Shen et al., 2011 |
| ω-3 fatty acids (GPR120, a functional receptor of the ω-3 fatty acids and GPR120-selective agonist) | ↓ Nitrosylation of Akt | Adipocytes; ↓ inflammation and insulin-sensitizing effects | Oh et al., 2014 |
| L-arginine or citrulline | ↑ eNOS–cGMP–PKG pathway; ↓ superoxide by UCP up-regulation, biogenesis of mitochondria; ↑ glutamate-cysteine ligase expression and GSH levels | Adipocytes and other cells; ↑ mitochondrial function, ↓ insulin sensitivity, ↓ fat mass | Jobgen et al., 2006; Lucotti et al., 2006; Petrović et al., 2009; Joffin et al., 2015 |
| Dietary polyphenols | ↑ SOD expression | Adipocytes; ↑ mitochondrial function, ↓ inflammation | Baret et al., 2013; Hatia et al., 2014; Marimoutou et al., 2015 |
render adipose tissue more susceptible to ONOO\textsuperscript{−}-mediated nitro-oxidative damage (Pacher et al., 2007). In addition, lower reduced GSH/Trx levels may decrease de-nitrosylation of SNO moieties and further increase the S-nitrosylated protein level. Overall, changes in intracellular GSH level correspond to changes in lipogenesis and adipogenesis (Galinier et al., 2006). However, the GSH level decreases in adipose tissues in subjects with long-lasting obesity (Jankovic et al., 2014). This may represent an early sign of redox dysbalance that, if not compensated by other redox molecules like the Trx system, leads to increased vulnerability to oxidant insult and decreased fat storage buffering capacity of adipocytes in obese subjects (Jankovic et al., 2014). Interestingly, subcutaneous, compared with visceral, adipose tissue characterizes greater adaptive capacity of antioxidant defence on GSH depletion (Jankovic et al., 2014).

**Perspectives – does targeting of the NO/superoxide ratio in adipose tissue hold promise?**

Targeting of the NO/O\textsuperscript{2−} ratio in adipose tissue may have relevance in the elucidation and management of obesity and diabetes pathogenesis. Although the use of antioxidant supplements may have beneficial effects on the overall health of diabetic patients, classical antioxidant therapy with vitamins failed to show benefits in curbing fat-specific insulin resistance, diabetes and related cardiovascular diseases (Münzel et al., 2010; Abdali et al., 2015). Adipose tissue in obesity is possibly a paradigm of parahomeostasis (Forman et al., 2014), whereas parallel increases in electrophiles, oxidants (superoxide, ONOO\textsuperscript{−}), nucleophiles and antioxidants (GSH, Trx and NADPH), in concert with increased nutrient metabolism in adipocytes, play important signalling roles, enabling adaptive expansion of adipose tissue in increasing nutrient intake (Jankovic et al., 2015b). Thus, antioxidant as well as the hormetic approach (to increase oxidants that would strengthen endogenous antioxidants) may interfere with the endogenous steady-state redox level in adipose tissue in obesity, thereby restricting its metabolic plasticity. The ideal approach is to increase NO bioavailability and/or simultaneously limit excessive superoxide formation (briefly summarized in Table 1). Currently, alternative antioxidant-promoting methods, such as l-arginine supplementation (Lucotti et al., 2006; McKnight et al., 2010), caloric restriction (Schulz et al., 2008) or use of SOD mimetics (Hoehn et al., 2009), are considered promising therapeutic strategies.

**Acknowledgements**

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (grant no. 173055) and the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS).

**Conflict of interest**

The authors declare no conflicts of interest.

**References**

Abdali D, Samson SF, Grover AK (2015). How effective are antioxidant supplements in obesity and diabetes? Med Princ Pract 24: 201–215.

Adida A, Spener F (2006). Adipocyte-type fatty acid-binding protein as intercompartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell. Biochim Biophys Acta 1761: 172–181.

Afanas’ev I (2010). Signaling of reactive oxygen and nitrogen species in diabetes mellitus. Oxid Med Cell Longev 3: 361–373.

Alam MA, Rahman MM (2014). Mitochondrial dysfunction in obesity: potential benefit and mechanism of co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord 13: 60.

Alemany M (2012). Regulation of adipose tissue energy availability through blood flow control in the metabolic syndrome. Free Radic Biol Med 52: 2108–2119.

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.

Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Facenda E et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5743.

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Facenda E et al. (2015e). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.

Anderson JW, Kendall CW, Jenkins DJ (2003). Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 22: 331–339.

Andersson K, Gaudiot N, Ribiere C, Elizalde M, Giudicelli Y, Arner P (2001). Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A 98: 12056–12061.

Baret P, Septembre-Malaterre A, Rigoulet M, Lefebvre d’Hellencourt C, Priault M, Gonthier MP et al. (2013). Dietary polyphenols preconditioning protects 3T3-L1 preadipocytes from mitochondrial alterations induced by oxidative stress. Int J Biochem Cell Biol 45: 167–174.

Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A (2009). Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 89: 27–71.

Basu S, Azarova NA, Font MD, King SB, Hogg N, Gladwin MT et al. (2008). Nitrite reductase activity of cytochrome c. J Biol Chem 283: 32590–32597.
Beckman JS, Koppenol WH (1996). Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424–C1437.

Bedard K, Krause KH (2007). The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245–313.

Bellamy TC, Garthwaite J (2001). Sub-second kinetics of the nitric oxide receptor, soluble guanylyl cyclase, in intact cerebellar cells. J Biol Chem 276: 4287–4292.

Beltrán B, Orsi A, Clementi E, Moncada S (2000). Oxidative stress and S-nitrosylation of proteins in cells. Br J Pharmacol 129: 953–960.

Berger M (1992). Risk of obesity in type II diabetes mellitus. Int J Obes Relat Metab Disord 16: S29–S33.

Bermlohr DA (2014). Exercise and mitochondrial function in adipose biology: all roads lead to NO. Diabetes 63: 2606–2608.

Blüher M (2009). Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117: 241–250.

Boden G, Cheung P, Kresse K, Homko C, Powers B, Ferrer I (2014). Insulin resistance is associated with diminished endoplasmic reticulum stress responses in adipose tissue of healthy and diabetic subjects. Diabetes 63: 2977–2983.

Bossy-Wetzel E, Lipton SA (2003). Nitric oxide signaling regulates mitochondrial number and function. Cell Death Differ 10: 757–760.

Brown GC (1995). Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 369: 136–139.

Brown GC (2001). Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta 1504: 46–57.

Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820.

Cannon B, Nedergaard J (2004). Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277–359.

Carey AL, Vorlander C, Reddy-Luthmooodoo M, Natoli AK, Formosa MF, Bertovic DA et al. (2014). Reduced UCP-1 content in vitro differentiated beige/brite adipocytes derived from preadipocytes of human subcutaneous white adipose tissue in obesity. PLoS One 9: e91997.

Carriere Y, Jeanson S, Berger-Muller M, Andre V, Chenouard E, Carriere Y (2009). AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104: 496–505.

Chen Z, Peng IC, Sun W, Su MI, Hsu PH, Fu Y et al. (2009). AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104: 496–505.
Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M et al. (2001). Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104: 342–345.

Elizalde M, Ryden M, van Harmelen V, Eneroth P, Gyllenhammar H, Holm C et al. (2000). Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res 41: 1244–1251.

Engeli S, Janke J, Gorzelniak K, Bönkje J, Ghose N, Lindschau C et al. (2004). Regulation of the nitric oxide system in human adipose tissue. J Lipid Res 45: 1640–1648.

Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000). Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87: 241–247.

Ferdinandy P, Schulz R (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia–reperfusion injury and preconditioning. Br J Pharmacol 138: 532–543.

Fernandez-Alfonso MS, Gil-Ortega M, García-Prieto CF, Aranguez I, Ruiz-Gayo M, Somoza B (2013). Mechanisms of perivascular adipose tissue dysfunction in obesity. Int J Endocrinol 2013: Article ID 402053, 8 pages.

Filip M, Maciag J, Nosalski R, Korbut R, Guzik T (2012). Endothelial dysfunction related to oxidative stress and inflammation in perivascular adipose tissue. PostepyBiochem 58: 186–194.

Finocchietto P, Barreyyo F, Holod S, Peralta J, Franco MC, Méndez C et al. (2008). Control of muscle mitochondria by insulin entails activation of Akt2-mtNOS pathway: implications for the metabolic syndrome. PLoS One 3: e1749.

Finocchietto PV, Holod S, Barreyyo F, Peralta JG, Alippe Y, Giovambattista A et al. (2011). Defective leptin-AMP-dependent kinase pathway induces nitric oxide release and contributes to mitochondrial dysfunction and obesity in ob/ob mice. Antioxid Redox Signal 15: 2395–2406.

Fisher-Wellman KH, Neuf a PD (2012). Linking mitochondrial bioenergetics to insulin resistance via redox biology. Trends Endocrinol Metab 23: 142–153.

Forman HJ, Davies KJ, Ursini F (2014). How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 66: 24–35.

Frayn KN (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia 45: 1201–1210.

Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW (2003). Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 27: 875–888.

Fridovich I (1995). Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97–112.

Frizzell N, Thomas SA, Carson JA, Baynes JW (2012). Mitochondrial stress causes increased succination of proteins in adipocytes in response to glucotoxicity. Biochem J 445: 247–254.

Frohnert BI, Sinaiko AR, Serrot FJ, Foncea RE, Moran A, Ikramuddin S et al. (2011). Increased adipose protein carbonylation in human obesity. J Biol Chem 286: 12682–12687.

Gao S, Chen J, Brodsky SV, Huang H, Adler S, Lee JH et al. (2004). Docking of endothelial nitric oxide synthase (eNOS) to the mitochondrial outer membrane: a pentabasic amino acid sequence in the autoinhibitory domain of eNOS targets a proteinase K-cleavable peptide on the cytoplasmic face of mitochondria. J Biol Chem 279: 15968–15974.

Garcia-Diaz D, Campion J, Milagro FI, Martinez JA (2007). Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem 305: 87–94.

Gauldion N, Jaubert AM, Charbonnier E, Sabourault D, Lacasa D, Giudicelli Y et al. (1998). Modulation of white adipose tissue lipolysis by nitric oxide. J Biol Chem 273: 13475–13481.

Gauldion N, Ribière C, Jaubert AM, Giudicelli Y (2000). Endogenous nitric oxide is implicated in the regulation of lipolysis through antioxidant-related effect. Am J Physiol Cell Physiol 279: C1603–C1610.

Georgescu A, Popov D, Constantan A, Nemecz M, Alexandru N, Cochrion D et al. (2011). Dysfunction of human subcutaneous fat arterioles in obesity alone or obesity associated with type 2 diabetes. Clin Sci (Lond) 120: 463–472.

Giordano A, Tonello C, Bulbarelli A, Cozzi V, Cinti S, Carruba MO et al. (2002). Evidence for a functional nitric oxide synthase system in brown adipocyte nucleus. FEBS Lett 514: 135–140.

Girousse A, Tavernier G, Valle C, Moro C, Mejbert N, Dinel AL et al. (2013). Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol 11: e1001485.

Goldstein BJ, Mahadev K, Wu X, Zhu L, Motoshima H (2005). Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal 7: 1021–1031.

Gow AJ, Farkouh CR, Munson DA, Posech-MA, Ischiropoulos H (2004). Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 287: L262–L268.

Gray SL, Vidal-Puig AJ (2007). Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 65: S7–S12.

Griendling KK, Sorescu D, Ushio-Fukai M (2000). NAD(P)H oxidase: a major contributor to cytokine-induced myocardial contractile failure. Circulation 101: 247–254.

Grimsrud PA, Picklo MJ Sr, Griffin TJ, Bernlohr DA (2007). Carboxylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics 6: 624–637.

Halliwell B, Gutteridge JMC (2007). In Halliwell B, Gutteridge JMC (eds). Free Radicals in Biology and Medicine 4th ed. Oxford University Press: New York.

Halpern B, Mancini MC, Halpern A (2014). Brown adipose tissue: what have we learned since its recent identification in human adults. Arq Bras Endocrinol Metabol 58: 889–899.

Han CY, Umemento T, Omer M, Den Hartigh L, Chiha T, LeBoeuf R et al. (2012). NADPH oxidase-derived reactive oxygen species increases expression of monocyte chemotactic factor genes in cultured adipocytes. J Biol Chem 287: 10379–10393.

Hao Q, Hansen JB, Petersen RK, Hallenberg P, Jørgensen C, Cinti S et al. (2010). ADD1/SREBP1c activates the PGC1-alpha promoter in brown adipocytes. Biochim Biophys Acta 1801: 421–429.
Hatia S, Septembre-Malaterre A, Le Sage F, Badiou-Bénéteau A, Baret P, Payet B et al. (2014). Evaluation of antioxidant properties of major dietary polyphenols and their protective effect on 3T3-L1 preadipocytes and red blood cells exposed to oxidative stress. Free Radic Res 48: 387–401.

Hiteit T, Krohn K, Albers S, Meinertz T (2000). Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 43: 1435–1438.

Hemmrich K, Gummersbach C, Paul NE, Goy D, Suschek CV, Kröncke KD et al. (2010). Nitric oxide and downstream second messenger cGMP and cAMP enhance adipogenesis in primary human preadipocytes. Cytotherapy 12: 547–553.

Henrich M, Hoffmann K, König P, Gruss M, Fischbach T, Gödecke A et al. (2002). Sensory neurons respond to hypoxia with NO production associated with mitochondria. Mol Cell Neurosci 20: 307–322.

Hess DT, Matsumoto A, Nudelman R, Stamler JS (2001). S-nitrosylation: spectrum and specificity. Nat Cell Biol 3: E46–E49.

Hill JO, Peters JC (1998). Environmental contributions to the obesity epidemic. Science 280: 1371–1374.

Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Hemmrich K, Gummersbach C, Paul NE, Goy D, Suschek CV, Kröncke KD et al. (2010). Nitric oxide and downstream second messenger cGMP and cAMP enhance adipogenesis in primary human preadipocytes. Cytotherapy 12: 547–553.

Horowitz JF (2001). Regulation of lipid mobilization and oxidation during exercise in obesity. Exerc Sport Sci Rev 29: 42–46.

Houstis N, Rosen ED, Lander ES (2006). Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944–948.

Hsu MF, Meng TC (2010). Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem 285: 7919–7928.

Huang C, Chen D, Xie Q, Yang Y, Shen W (2013). Nebivolol stimulates mitochondrial biogenesis in 3T3-L1 adipocytes. Biochem Biophys Res Commun 438: 211–217.

Ignarro LJ (1990a). Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 67: 1–7.

Ignarro LJ (1990b). Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16: 477–483.

Iozzo P (2009). Viewpoints on the way to the consensus session: where does insulin resistance start? The adipose tissue. Diabetes Care 32: S168–S173.

Irie Y, Saeki M, Kamisaki Y, Martin E, Murad F (2003). Histone H1.2 is a substrate for denitrase, an activity that reduces nitrotyrosine immunoreactivity in proteins. Proc Natl Acad Sci U S A 100: 5634–5639.

Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD (1992). Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298: 431–437.

Jankovic A, Golic I, Markelic M, Stancic A, Otasevic V, Buzadzic B et al. (2015a). Two key temporally distinguishable molecular and cellular components of white adipose tissue browning during cold acclimation. J Physiol 593: 3267–3280.

Jankovic A, Korac A, Buzadzic B, Otasevic V, Stancic A, Daiber A et al. (2015b). Redox implications in adipose tissue (dys)function—a new look at old acquaintances. Redox Biol 6: 19–32.

Jankovic A, Korac A, Srdic-Galic B, Buzadzic B, Otasevic V, Stancic A et al. (2014). Differences in the redox status of human visceral and subcutaneous adipose tissues-relationships to obesity and metabolic risk. Metabolism 63: 661–671.

Jaubert AM, Penot G, Niang F, Durant S, Forest C (2012). Rapid nitration of adipocyte phosphoenolpyruvate carboxykinase by leptin reduces glyceroneogenesis and induces fatty acid release. PLoS One 7: e40650.

Jeanson Y, Carriere A, Castella L (2015). A new role for browning as a redox and stress adaptive mechanism? Front Endocrinol (Lausanne) 6: 158.

Jeon MJ, Leem J, Ko MS, Jang JE, Park HS, Kim HS et al. (2012). Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes. Exp Mol Med 44: 562–570.

Jezek P, Plescita-Hlavitá L, Smolková K, Rossignol R (2010). Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development. Int J Biochem Cell Biol 42: 604–609.

Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G (2006). Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 17: 571–578.

Jobgen W, Meininger CJ, Jobgen SC, Li P, Lee MJ, Smith SB et al. (2009). Dietary l-arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J Nutr 139: 230–237.

Joffin N, Jaubert AM, Bamba J, Barouki R, Noirez P, Forest C (2015). Acute induction of uncoupling protein 1 by citrulline in cultured explants of white adipose tissue from lean and high-fat-diet-fed rats. Adipocyte 4: 129–134.

Jones DP (2008). Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 295: C849–C868.

Kaminski Y, Wada K, Bian K, Balabanli B, Davis K, Martin E et al. (1998). An activity in rat tissues that modifies nitrotyrosine-containing proteins. Proc Natl Acad Sci U S A 95: 11584–11589.

Kawasaki N, Asada R, Saito A, Kanemoto S, Imaizumi K (2012). Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep 2: 799.

Kaneki M, Shimizu N, Yamada D, Chang K (2005). Proteomic analysis of protein containing proteins. Proc Natl Acad Sci U S A 95: 11584–11589.

Kanski J, Hong SJ, Schöneich C (2005). Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem 280: 24261–24266.

Karbach S, Wenzel P, Waismann A, Munzel T, Daiber A et al. (2014). eNOS uncoupling in cardiovascular diseases—the role of oxidative stress and inflammation. Curr Pharm Des 20: 3579–3594.

Kashiwagi S, Atochin DN, Li Q, Schleicher M, Pong T, Sessa WC et al. (2013). eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity. Biochem Bioph Res Commun 431: 284–290.

Kashyap SR, Defronzo RA (2007). The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 4: 13–19.
Keller MP, Attie AD (2010). Physiological insights gained from gene expression analysis in obesity and diabetes. Annu Rev Nutr 30: 341–364.

Kelly DP, Scarpulla RC (2004). Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18: 357–368.

Klatt P, Cacho J, Crespo MD, Herrera E, Ramos P (2000). Nitric oxide inhibits isoproterenol-stimulated adipocyte lipolysis through oxidative inactivation of the beta-agonist. Biochem J 32: 485–493.

Koeck T, Stuehr DJ, Aulak KS (2005). Mitochondria and regulated tyrosine nitration. Biochem Soc Trans 33: 1399–1403.

Koeck T, Willard B, Crabw JB, Kinter M, Stuehr DJ, Aulak KS (2009). Glucose-mediated tyrosine nitration in adipocytes: targets and consequences. Free Radic Biol Med 46: 884–892.

Koh EH, Park JY, Park HS, Jeon MJ, Ryu JW, Kim M et al. (2007). Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 56: 2973–2981.

Koppenol WH (2001). 100 years of peroxynitrite chemistry and superoxide. Chem Res Toxicol 14: 834–842.

Kozak LP, Koza RA, Anunciado-Koza R (2010). Brown fat thermogenesis and body weight regulation in mice: relevance to humans. Int J Obes (Lond) 34: S23–S27.

Krieger-Brauer HI, Kather H (1992). Human fat cells possess a plasma membrane-bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest 89: 1006–1013.

Krieger-Brauer HI, Kather H (1995). Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H2O2 generation in 3T3 L1-cells. Biochem J 307: 549–556.

Kröller-Schön S, Steven S, Kossmann S, Scholz A, Daub S, Oelze M et al. (2014). Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-dependent on glutathione and possible role of S-nitrosation. J Biol Chem 289: 247–266.

Krumenacker JS, Murad F (2006). NO-cGMP signaling in development and stem cells. Mol Genet Metab 87: 311–314.

Kuzkaya N, Weissmann N, Harrison DG, Dikalov S (2003). Interactions of peroxynitrite, tetrahydrobipterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278: 22546–22554.

Lafontan M (2013). Adipose tissue and adipocyte dysregulation. Diabetes Metab 40: 16–28.

Lan P, Hao G, Gross SS (2001). S-nitrosylation is emerging as a specific and fundamental posttranslational protein modification: head-to-head comparison with O-phosphorylation. Sci STKE 2001. re1

Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP et al. (2005). The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 280: 4617–4626.

Liu Z, Rudd MA, Freedman JE, Loscalzo J (1998). S-Nitrosothiol reactions are involved in the metabolic fate and biological actions of nitric oxide. J Pharmacol Exp Ther 284: 526–534.

Lu RH, Ji H, Chang ZG, Su SS, Yang GS (2010). Mitochondrial development and the influence of its dysfunction during rat adipocyte differentiation. Mol Biol Rep 37: 2173–2182.

Lucotti P, Setola E, Monti LD, Galluccio E, Costa S, Sandoli EP et al. (2006). Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab 291: E906–E912.

Lumeng CN, Bodzin JL, Saltiel AR (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175–184.

Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW et al. (2008). Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci U S A 105: 18525–18530.

Margaritis M, Antonopoulos AS, Digby J, Lee R, Reilly S, Coutinho P et al. (2013). Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 127: 2209–2221.

Marinoumoutou M, Le Sage F, Smadja J, Lefebvre d’Hellencourt C, Gonthier MP, Robert-Da Silva C (2015). Antioxidant polyphenol-rich extracts from the medicinal plants Antirrhinum majus, Doratocystis opetulum and Goanuia mauritiana protect 3T3-L1 adipocytes against H2O2, TNFε and LPS inflammatory mediators by regulating the expression of superoxide dismutase and NF-κB genes. J Inflamm (Lond) 12: 10.

Maritim AC, Sanders RA, Watkins JB 3rd (2003). Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24–38.

Martínez-Morua A, Soto-Urqueta MG, Franco-Robles E, Zúñiga-Trujillo I, Campos-Cervantes A, Perez-Vazquez V et al. (2013). Curcumin decreases oxidative stress in mitochondria isolated from liver and kidneys of high-fat diet-induced obese mice. J Asian Nat Prod Res 15: 905–915.

Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H et al. (2008). Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 57: 1071–1077.

Mayer B, Schrammel A, Klatt P, Koesling D, Schmidt K (1995). Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. J Biol Chem 270: 17355–17360.

McKnight JR, Satterfield MC, Jobgen WS, Smith SB, Spencer TE, Meininger CJ et al. (2010). Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids 39: 349–357.

Merial C, Bouloumie A, Trocheris V, Lafontan M, Galitzky J (2000). Nitric oxide-dependent downregulation of adipocyte UCP-2 expression by tumor necrosis factor-alpha. Am J Physiol Cell Physiol 279: C1106–C1107.

Moncada S, Palmer RM, Higgs EA (1989). The biological significance of nitric oxide formation from L-arginine. Biochem Soc Trans 17: 642–644.

Mondoro TH, Shafer BC, Vostal JG (1997). Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. Free Radic Biol Med 22: 1055–1063.
Mouche S, Mkaddem SB, Wang W, Katic M, Tseng YH, Carnescelli S et al. (2007). Reduced expression of the NADPH oxidase NOX4 is a hallmark of adipocyte differentiation. Biochem Biophys Acta 1773: 1015–1027.

Münzel T, Gori T (2009). Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 54: 1491–1499.

Münzel T, Gori T, Bruno RM, Taddei S (2010). Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 31: 2741–2748.

Münzel T, Sinning C, Post F, Warnholtz A, Schulz E (2008). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40: 180–196.

Murad F (1988). Role of cyclic GMP in the mechanism of action of nitrovasodilators, endothelium-dependent agents and atrial natriuretic peptide. Biochem Soc Trans 16: 490–492.

Murad F, Ishii K, Förstermann U, Gorsky L, Kerwin JF Jr, Pollock J et al. (1990). EDRF is an intracellular second messenger and autacoid to regulate cyclic GMP synthesis in many cells. Adv Second Messenger Phosphoprotein Res 24: 441–448.

Nagababu E, Ramasamy S, Abernethy DR, Riffkind JM (2003). Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. J Biol Chem 278: 46349–46356.

Netzer N, Gatterer H, Faulhaber M, Burtscher M, Pramsohler S, Pesta D (2015). Hypoxia, oxidative stress and fat. Biomolecules 5: 1143–1150.

Niang F, Benelli C, Ribière C, Collinet M, Mehebik-Mojaat N, Penot G et al. (2011). Leptin induces nitric oxide-mediated inhibition of lipolysis and glyceroenogenesis in rat white adipose tissue. J Nutr 141: 4–9.

Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD (2010). Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain. Biochemistry 49: 2433–2442.

Nisoli E, Carruba MO (2006). Nitric oxide and mitochondrial biogenesis. J Cell Sci 119: 2855–2862.

Nisoli E, Clementi E, Carruba MO, Moncada S (2007). Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 100: 795–806.

Nohl H, Staniek K, Sobhian B, Bahrami S, Redl H, Kozlov AV (2000). Mitochondria recycle nitrate back to the bioregulator nitric monoxide. Acta Biochim Pol 47: 913–921.

Nomiyama T, Igarashi Y, Taka H, Mineki R, Uchida T, Oghihara T et al. (2004). Reduction of insulin-stimulated glucose uptake by peroxy nitrite is concurrent with tyrosine nitration of insulin receptor substrate-1. Biochem Biophys Res Commun 320: 639–647.

Oberkofer H, Dallinga G, Liu YM, Hell E, Krempfer F, Patsch W (1997). Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J Lipid Res 38: 2125–2133.

Oh da Y, Walenta A, Akiyama T, Lagakos WS, Lackey D, Pessentheiner AR et al. (2014). A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20: 942–947.

Ovadia H, Haim Y, Nov O, Almog O, Kovsan J, Bashan N et al. (2011). Increased adipocyte S-nitrosylation targets anti-lipolytic action of insulin: relevance to adipose tissue dysfunction in obesity. J Biol Chem 286: 30433–30443.

Pacher P, Beckman JS, Laiadet L (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315–424.

Pechánová O, Varga ZV, Cebová M, Gírich Z, Pacher P, Ferdinandy P (2015). Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol 172: 1415–1433.

Perez-Matute P, Neville MJ, Tan GD, Frayn KN, Karpe F (2009). Transcriptional control of human adipose tissue blood flow. Obesity (Silver Spring) 17: 681–688.

Perreault M, Marette A (2001). Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7: 1138–1143.

Petrović V, Buzdžić B, Korać A, Vasiljević A, Janković A, Korać B (2009). L-Arginine supplementation induces glutathione synthesis in interscapular brown adipose tissue through activation of glutamate-cysteine ligase expression: The role of nitric oxide. Chem Biol Interact 182: 204–212.

Pilon G, Charbonneau A, White PJ, Dallaire P, Perreault M, Kapur S et al. (2010). Endotoxin mediated-NO induction causes insulin resistance via ONOO induced tyrosine nitration of IRS-1 in skeletal muscle. PLoS One 5.e15912

Pilon G, Dallaire P, Marette A (2004). Inhibition of inducible nitric oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 279: 20767–20774.

Prendergast BD, Sagach VF, Shah AM (1997). Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 96: 1320–1329.

Priyanka A, Anusree SS, Nisha VM, Raghu KG (2014a). Curcumin improves hypoxia induced dysfunctions in 3T3-L1 adipocytes by protecting mitochondria and down regulating inflammation. Biofactors 40: 513–523.

Priyanka A, Nisha VM, Anusree SS, Raghu KG (2014b). Bilobalide attenuates hypoxia induced oxidative stress, inflammation, and mitochondrial dysfunctions in 3T3-L1 adipocytes via its antioxidant potential. Free Radic Res 48: 1206–1217.

Rawlingson A, Shendi K, Greenacre SA, England TG, Jenner AM, Poston RN et al. (2003). Functional significance of inducible nitric oxide synthase induction and protein nitration in the thermally injured cutaneous microvasculature. Am J Pathol 162: 1373–1380.

Ribiere C, Jaubert AM, Gautier N, Sabourault D, Marcus ML, Boucher JL et al. (1996). White adipose tissue nitric oxide synthase: a potential source for NO production. Biochem Biophys Res Commun 222: 706–712.

Ribiere C, Jaubert AM, Sabourault D, Lacasa D, Giudicelli Y (2002). Insulin stimulates nitric oxide production in rat adipocytes. Biochem Biophys Res Commun 291: 394–399.

Rivera L, Moron R, Zarzuelo A, Galisteo M (2009). Long-term resveratrol administration reduces metabolic disorders and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77: 1053–1063.

Roberts LD (2015). Does inorganic nitrate say NO to obesity by browning white adipose tissue? Adipocyte 4: 311–314.

Roberts LD, Ashmore T, Kotwica AO, Murfitt SA, Fernandez BO, Feilisch M et al. (2015). Inorganic nitrate promotes the browning of white adipose tissue through the nitrate–nitrite–nitric oxide pathway. Diabetes 64: 471–484.

Rodriguez-Juárez F, Aguirre E, Cadenas S (2007). Relative sensitivity of soluble guanylate cyclase and mitochondrial respiration to endogenous nitric oxide at physiological oxygen concentration. Biochem J 405: 223–231.
Rossmeisl M, Syrový I, Baumruk F, Flachs P, Janovská P, Kopec ký J (2000). Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue. FASEB J 14: 1793–1800.

Roy D, Perreault M, Marette A (1998). Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol 274: E692–E699.

Rubbo H, Darley-Usmar V, Freeman BA (1996). Nitric oxide regulation of tissue free radical injury. Chem Res Toxicol 9: 809–820.

Rutkowski JM, Stern JH, Scherer PE (2015). The cell biology of fat accumulation. J Biol Chem 282: 32424–32431.

Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD (2000). Mice with targeted disruption of the adipocyte fatty acid-binding protein exhibit insulin resistance. Diabetes 49: 684–690.

Trentin JG (2013). Peroxynitrite-driven mechanisms in diabetes and insulin resistance - the latest advances. Curr Med Chem 18: 280–290.

Stamler JS (1995). S-nitrosothiols and the bioregulatory actions of nitrogen oxides through reactions with thiol groups. Curr Top Microbiol Immunol 196: 19–36.

Stamler JS, Meissner G (2001). Physiology of nitric oxide in skeletal muscle. Physiol Rev 81: 209–237.

Stamler JS, Singel DJ, Loscalzo J (1992). Biochemistry of nitric oxide and its redox-activated forms. Science 258: 1898–1902.

Toledo JC Jr, Augusto O (2012). Connecting the chemical and biological properties of nitric oxide. Chem Res Toxicol 25: 975–989.

Turrens JF, Boveris A (1980). Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191: 1–16.

Vanin AF, Bevers LM, Slama-Schwok A, van Faassen EE (2007). Nitric oxide synthase exhibits nitrate reductase activity in the stomach. Mol Cells 23: 333–334.

Verhaar MC, Stroes E, Rabelink TJ (2002). Factors and cardiovascular disease. Arterioscler Thromb Vasc Biol 22: 6–13.

Villa LM, Salas E, Darley-Usmar VM, Radomski MW, Moncada S (1994). Peroxynitrite induces both vasodilation and impaired relaxation of isolated rat aortic rings. J Cardiovasc Pharmacol 23: 448–453.

Southan C, Sharman JL, Benson HE, Facenda E, Pawson AJ, Alexander SF et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl. Acids Res. 44 (Database Issue): D1054–D1066.
vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci U S A 91: 12383–12387.

Villanueva C, Giulivi C (2010). Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med 49: 307–316.

Vorbach C, Harrison R, Capecchi MR (2003). Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol 24: 512–517.

Vosselman MJ, Brans B, van der Lans AA, Wierts R, van Baak MA, Mottaghy FM et al. (2013b). Brown adipose tissue activity after a high-calorie meal in humans. Am J Clin Nutr 98: 57–64.

Vosselman MJ, van Marken Lichtenbelt WD, Schrauwen P (2013a). Energy dissipation in brown adipose tissue: from mice to men. Mol Cell Endocrinol 379: 43–50.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003). Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808.

Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszky J et al. (2004). Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114: 1281–1289.

Wink DA, Mitchell JB (1998). Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25: 434–456.

Wood IS, de Heredia FP, Wang B, Trayhurn P (2009). Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 68: 370–377.

Wright VP, Reiser PJ, Clanton TL (2009). Redox modulation of global phosphatase activity and protein phosphorylation in intact skeletal muscle. J Physiol 587: 5767–5781.

Wu G, Collins JK, Perkins-Veazie P, Siddiq M, Dolan KD, Kelly KA et al. (2007). Dietary supplementation with watermelon pomace juice enhances arginine availability and ameliorates the metabolic syndrome in Zucker diabetic fatty rats. J Nutr 137: 2680–2685.

Yang L, Calay ES, Fan J, Arduini A, Kunz RC, Gygi SP et al. (2015). S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction. Science 349: 500–506.

Yang Y, Loscalzo J (2005). S-Nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci U S A 102: 117–122.

Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA, Kaneki M (2005). S-Nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 280: 7511–7518.

Yeop Han C, Kargi AY, Omer M, Chan CK, Wahitsch M, O’Brien KD et al. (2010). Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 59: 386–396.

Yin R, Fang L, Li Y, Xue P, Li Y, Guan Y et al. (2015). Pro-inflammatory macrophages suppress PPARγ activity in adipocytes via S-nitrosylation. Free Radic Biol Med 89: 895–905.

Yu Y, Rajapakse AG, Montani JP, Yang Z, Ming XF (2014). p38 mitogen-activated protein kinase is involved in arginase-II-mediated eNOS-uncoupling in obesity. Cardiovasc Diabetol 13: 113.

Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC (1998). Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun 249: 767–772.

Zhou J, He X, Huang K (2009). Bidirectional regulation of insulin receptor autophosphorylation and kinase activity by peroxynitrite. Arch Biochem Biophys 488: 1–8.

Zhou J, Huang K (2009). Peroxynitrite mediates muscle insulin resistance in mice via nitration of IRbeta/IRS-1 and Akt. Toxicol Appl Pharmacol 241: 101–110.

Zmuda-Trzebiatowska E, Manganiello V, Degerman E (2007). Novel mechanisms of the regulation of protein kinase B in adipocytes; implications for protein kinase A, Epac, phosphodiesterases 3 and 4. Cell Signal 19: 81–86.